EA
TVTX icon

Emerald Advisers’s Travere Therapeutics TVTX Stock Holding History

Emerald Advisers’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.3M Sell
1,557,196
-36,988
-2% -$1.11M 1.46% 12
2025
Q4 		$60.9M Sell
1,594,184
-552,583
-26% -$18M 1.88% 5
2025
Q3 		$51.3M Buy
2,146,767
+55,407
+3% +$1.04M 1.64% 11
2025
Q2 		$31M Buy
2,091,360
+14,187
+0.7% +$235K 1.13% 28
2025
Q1 		$37.2M Sell
2,077,173
-48,571
-2% -$986K 1.68% 11
2024
Q4 		$37M Buy
2,125,744
+165,085
+8% +$2.92M 1.43% 13
2024
Q3 		$27.4M Buy
1,960,659
+323,513
+20% +$3.37M 1.06% 33
2024
Q2 		$13.5M Sell
1,637,146
-112,255
-6% -$756K 0.56% 62
2024
Q1 		$13.5M Buy
1,749,401
+703,252
+67% +$5.93M 0.54% 77
2023
Q4 		$9.4M Sell
1,046,149
-14,153
-1% -$103K 0.4% 96
2023
Q3 		$9.48M Buy
1,060,302
+417,250
+65% +$5.89M 0.46% 92
2023
Q2 		$9.88M Buy
+643,052
New +$11.7M 0.43% 91

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Emerald Advisers's TVTX Position: Q1 2026 in Review

Emerald Advisers reduced its Travere Therapeutics (TVTX) stake by 2.3% in Q1 2026, selling an estimated $1.11M and leaving 1,557,196 shares worth $46.3M. The position accounts for 1.46% of the portfolio, ranked #12.

Emerald Advisers first reported a position in TVTX in Q2 2023 and has held it in 12 quarters since. The position peaked at $60.9M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Emerald Advisers held 1,557,196 shares of Travere Therapeutics worth $46.3M as of Q1 2026.
  • Emerald Advisers sold 36,988 Travere Therapeutics shares in Q1 2026, an estimated $1.11M.
  • Travere Therapeutics made up 1.46% of Emerald Advisers's portfolio in Q1 2026, its #12 holding.
  • Emerald Advisers first reported a position in Travere Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • Emerald Advisers's Travere Therapeutics position peaked at $60.9M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Emerald Advisers's 13F filing for Q1 2026, filed 4 May 2026.